Drugs / GW870086
last change Aug 2011 re-read 2 minutes ago

GW870086

also known as GW870086X

Small molecule

Developed for
asthma · atopic eczema
Investigated by
GlaxoSmithKline

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials
Phase 1 NCT01381445 Apr → Jul 2011 atopic eczema GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT01160003 Jul → Nov 2010 asthma GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00549497 Sep 2007 → Jan 2008 asthma GlaxoSmithKline Completed No outcome recorded
Phase 1 NCT00483899 Oct 2005 → Dec 2006 asthma GlaxoSmithKline Completed No outcome recorded
Phase 24 trials
Phase 2 NCT01299610 Dec 2010 → Mar 2011 atopic eczema GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT01245426 Dec 2010 → Jul 2011 asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00945932 Jul → Dec 2009 asthma GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00857857 Feb → Nov 2009 asthma GlaxoSmithKline Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as GW870086 ClinicalTrials.gov intervention name — accepted as the source's own label NCT01381445
2

NCT01245426

NCT01299610

Known as GW870086X ClinicalTrials.gov intervention name — accepted as the source's own label NCT01160003
4

NCT00857857

NCT00549497

NCT00483899

NCT00945932

Action Activate “GW870086X is a potent glucocorticoid agonist in human in vitro functional assays” NCT01160003
Modality Small molecule CHEMBL4297388
Route Inhaled “Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times” NCT00483899